Keytruda

paper airplane
Biotech

Inhibrx says OX40 agonist’s durability confirmed by ph. 2 win

Inhibrx’s CEO argued that the 9.6 months of PFS demonstrated by its OX40 agonist has proven the therapy’s durability in treating head and neck cancer.
Will Maddox Sep 8, 2026 10:22am
Moderna ESMO

Merck-Moderna vaccine data spur talk of Keytruda-like impact

Aug 20, 2026 9:25am
Person throwing piece of paper into full waste bin
Favicon Fierce Pharma

Nature retracts provocative PD-1 time-of-day study

Jun 24, 2026 11:00am
ASCO
Favicon Fierce Pharma

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am
Magnifying glass focusing on womens health

OSE turns up the heat on ovarian cancer with phase 2 win

May 22, 2026 7:14am
lung
Favicon Fierce Pharma

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm